Moreover, the implementation of STAT3-targeting therapies must consider the marked heterogeneity of CAFs and they should be tailored towards suppressing tumor-promoting populations while preserving those that do not contribute to disease to essentially promote an anti-tumor response in the TME. This evidence concerns the gene STAT3 and neoplasm.